The Nobel Assembly at Karolinska Institutet announced the award of the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, Peter...
Read full article →San Francisco-based Vial has dosed the first asthma patient in a Phase Ib trial of its IL-13/TSLP bispecific antibody, which is engineered for potential...
La Jolla, California-based Equillium (Nasdaq: EQ) has received Australian regulatory and ethics clearance to begin a first-in-human Phase I trial of EQ504,...
Genmab (Nasdaq: GMAB) and AbbVie reported that adding epcoritamab to R-CHOP chemotherapy reduced the risk of disease progression or death by 51% in newly...
South San Francisco-based TRexBio has filed an amended S-1 to raise approximately USD 116.7 million to USD 133.3 million in a Nasdaq IPO, offering 8.33...
Gate Bioscience expanded its discovery partnership with Eli Lilly in a deal potentially worth more than USD 870 million. The agreement adds one target, with...
RougeTx, based in the Netherlands, has launched with a USD 58 million Series A to advance RTX-001, its lead programme for hereditary haemorrhagic...
Italy-based Italfarmaco S.p.A. and San Francisco-based VeriSIM Life, Inc. have entered a discovery collaboration to develop novel small-molecule inhibitors...
Sernova Biotherapeutics (TSX: SVA; OTC: SEOVF) and Seraxis Holdings, Inc. have closed a USD 11.2 million financing to support their proposed merger into...
Researchers at Washington University School of Medicine in St. Louis found that blocking the chemokine receptor CXCR3 reduced T-cell infiltration into the...
Jiangsu Nhwa Pharmaceutical Co. (Shenzhen Stock Exchange: 002262) announced the grant of an exclusive license to Tennessee-based Somnivera, Inc. for...
Suzhou, China-based Ractigen Therapeutics presented first-in-human Phase I data for RAG-18, a small activating RNA therapeutic for Duchenne muscular...
Genmab (Nasdaq: GMAB) reported that rinatabart sesutecan (Rina-S), its folate receptor alpha (FRα)-targeted antibody-drug conjugate, achieved a confirmed...
The US FDA approved Jaypirca (pirtobrutinib) as monotherapy for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma...
Italy-based Italfarmaco S.p.A. and Japan-based JCR Pharmaceuticals Co., Ltd. (Tokyo Stock Exchange: 4552) have agreed an exclusive license covering...
BioMarin Pharmaceutical (Nasdaq: BMRN) reported long-term efficacy and safety data from the PROPEL open-label extension study of cipaglucosidase alfa...
Free, systematic R&D and deal news. Daily.